DEDrew Ellershaw

Drew Ellershaw

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Drew Ellershaw has a total of 53 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Cell-Free DNA in Pediatric Solid Organ Transplantation Using a New Detection Method of Separating Donor-Derived from Recipient Cell-Free DNA

    by Evgenia Preka, Drew Ellershaw, Natalie Chandler, Helena Ahlfors, Helen Spencer, Lyn S Chitty, Matthew J Fenton, Stephen D Marks

    Background: The use of cell-free DNA (cfDNA) as a noninvasive biomarker to detect allograft damage is expanding rapidly. However, quantifying the low fraction of donor-derived cfDNA (ddcfDNA) is challenging and requires a highly sensitive technique. ddcfDNA detection through unique donor single nucleotide polymorphisms (SNPs) is a recent new approach, however there are limited data in pediatric solid organ transplant (SOT) recipients. Methods: We developed an assay using a combination of 61 SNPs to quantify the ddcfDNA accurately using a custom R script to model for both the patient and donor genotypes requiring only a single sample from the allograft recipient. Performance of the assay was validated using genomic DNA (gDNA), cfDNA and donor samples where available. Results: The R “genotype-free” method gave results comparable to when using the known donor genotype. applicable to both related and unrelated pairs and can reliably measure ddcfDNA (limit of blank, below 0.12%; limit of detection, above 0.25%; limit of quantification 0.5% resulting in 84% accuracy). 159 pediatric SOT recipients (kidney, heart, and lung) were tested without the need for donor genotyping. Serial sampling was obtained from 82 patients. Conclusion: We have developed and validated a new assay to measure the fraction of ddcfDNA in the plasma of pediatric SOT recipients. Our method can be applicable in any donor-recipient pair without the need for donor genotyping and can provide results in 48 h at a low cost. Additional prospective studies are required to demonstrate its clinical validity in a large cohort of pediatric SOT recipients.


  • Contiguous gene deletion of TBX5 and TBX3: report of another case

    by Francesca Forzano, Patricia A. Foley, Morgan R. Keane, Caroline E. Brain, Gill D. Smith, Robert W. Yates, Drew Ellershaw, Alistair D. Calder, Richard H. Scott


  • Stem cell transplantation for tetratricopeptide repeat domain 7A deficiency: long-term follow-up

    by Jochen Kammermeier, Giovanna Lucchini, Sung-Yun Pai, Austen Worth, Dyanne Rampling, Persis Amrolia, Juliana Silva, Robert Chiesa, Kanchan Rao, Gabriele Noble-Jamieson, et al.

    Mutations in the tetratricopeptide repeat domain 7A (TTC7A)gene cause a severe form of very early-onset inflammatory bowel disease (VEOIBD). TTC7A has a crucial role in chaperoning the enzyme phosphatidylinositol-4-Kinase-3-alpha from the Trans-Golgi apparatus to the plasma membrane to facilitate phosphorylation of phosphatidylinositol (PI). The composition of the plasma membrane in particular levels of phosphorylated PI (PI-4P) are crucial for preserving epithelial cell polarity and survival . The clinical spectrum of the disease varies from multiple intestinal atresias (MIA) to severe autoimmune enterocolitis clinically evident by infantile-onset intestinal obstruction/failure, bleeding and diarrhoea. Furthermore, the disease can be associated with severe immunodeficiency or autoimmune phenomena owing to the central role of TTC7A in thymic architecture. Limited published data on TTC7A deficient patients suggests a median survival <12 months of age. Allogeneic hematopoietic stem cell transplantation (HSCT) represents a possible treatment option for therapy-refractory VEOIBD with or without genetic diagnosis, especially when associated with immunological impairment. Moreover, evidence on the interaction between haematopoietic donor and host epithelial cells in stem cell transplantation might lead to potential benefit of HSCT in certain epithelial disorder. TTC7A deficient patients with associated immunodeficiency may therefore benefit from HSCT, however the effect of engrafted donor cells on chronic intestinal inflammation and gut epithelial tissue regeneration is unknown. Follow-up data on HSCT in TTC7A-deficiency is required to understand the impact of this treatment on the disease phenotype and to guide the management of future cases. In this study, we report the clinical and histological evolution of four TTC7A-deficient patients who are alive 19 to 114 months post HSCT


  • Trisomy 21 Mid-Trimester Amniotic Fluid Induced Pluripotent Stem Cells Maintain Genetic Signatures During Reprogramming: Implications for Disease Modeling and Cryobanking

    by Caterina Pipino, Sayandip Mukherjee, Anna L David, Michael P. Blundell, Steven W. Shaw, Peggy Sung, Panicos Shangaris, Jonathan J. Waters, Drew Ellershaw, Marina Cavazzana, et al.

    Trisomy 21 is the most common chromosomal abnormality and is associated primarily with cardiovascular, hematological, and neurological complications. A robust patient-derived cellular model is necessary to investigate the pathophysiology of the syndrome because current animal models are limited and access to tissues from affected individuals is ethically challenging. We aimed to derive induced pluripotent stem cells (iPSCs) from trisomy 21 human mid-trimester amniotic fluid stem cells (AFSCs) and describe their hematopoietic and neurological characteristics. Human AFSCs collected from women undergoing prenatal diagnosis were selected for c-KIT(+) and transduced with a Cre-lox-inducible polycistronic lentiviral vector encoding SOX2, OCT4, KLF-4, and c-MYC (50,000 cells at a multiplicity of infection (MOI) 1-5 for 72 h). The embryonic stem cell (ESC)-like properties of the AFSC-derived iPSCs were established in vitro by embryoid body formation and in vivo by teratoma formation in RAG2(-/-), γ-chain(-/-), C2(-/-) immunodeficient mice. Reprogrammed cells retained their cytogenetic signatures and differentiated into specialized hematopoietic and neural precursors detected by morphological assessment, immunostaining, and RT-PCR. Additionally, the iPSCs expressed all pluripotency markers upon multiple rounds of freeze-thawing. These findings are important in establishing a patient-specific cellular platform of trisomy 21 to study the pathophysiology of the aneuploidy and for future drug discovery.